Astellas' XTANDI™ (Enzalutamide) Granted European Com

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Barcelona , Comunidad Autonoma De Cataluna , Spain , Canada , Tokyo , United States , America , Antonio Alcaraz , Ahsan Arozullah , Drug Administration , University Hospital Clinic Of Barcelona , European Medicines Agency , European Union , Committee For Medicinal Products Human Use , American Society Of Clinical Oncology , Head Of Oncology Development , European Association Of Urology , European Commission , Department Of Urology , Prnewswire Astellas Pharma Inc , Astellas Pharma Inc , European Association , University Hospital Clinic , Europa Uomo , Senior Vice President , Oncology Development , Medicinal Products , Human Use , Receives Positive , Medicines Agency Validates Type , Pfizer Led Phase , Important Safety Information , Product Characteristics , Focus Area Approach , Biochemically Recurrent Prostate , Clin Pract , Prostate Cancer ,